Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

IDYA

Ideaya Biosciences Inc

Oct 24 • 04:00PM ET

29.18

+0.76 2.67 %

Healthcare • Biotechnology • USA • NASD

Peers: EXEL INCY NBIX BPMC ARGX FATE YMAB NERV GOSS ENTA

| Held by: VTI IWM XBI VXF IWN IBB SCHA VTWO VHT DFAS

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.79	Insider Own	8.00%	Shs Outstand	87.64M	Perf Week	-0.27%
Market Cap	2.56B	Forward P/E	-	EPS next Y	-3.36	Insider Trans	0.00%	Shs Float	80.64M	Perf Month	13.59%
Enterprise Value	1.91B	PEG	-	EPS next Q	-0.83	Inst Own	104.12%	Short Float	10.41%	Perf Quarter	16.63%
Income	-331.80M	P/S	365.35	EPS this Y	-0.52%	Inst Trans	-2.51%	Short Ratio	6.75	Perf Half Y	53.58%
Sales	7.00M	P/B	2.66	EPS next Y	0.42%	ROA	-32.93%	Short Interest	8.39M	Perf YTD	13.54%
Book/sh	10.95	P/C	3.82	EPS next 5Y	4.46%	ROE	-35.09%	52W High	32.67 -10.68%	Perf Year	-3.44%
Cash/sh	7.64	P/FCF	-	EPS past 3/5Y	-33.53% -0.01%	ROIC	-33.65%	52W Low	13.45 116.95%	Perf 3Y	85.51%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-36.96% -	Gross Margin	42.56%	Volatility	4.32% 5.01%	Perf 5Y	122.58%
Dividend TTM	-	EV/Sales	273.47	EPS Y/Y TTM	-73.55%	Oper. Margin	-5488.94%	ATR (14)	1.37	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.39	Sales Y/Y TTM	-41.48%	Profit Margin	-4740.03%	RSI (14)	60.57	Recom	1.26
Dividend Gr. 3/5Y	- -	Current Ratio	12.39	EPS Q/Q	-29.40%	SMA20	4.96%	Beta	0.12	Target Price	47.88
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	11.41%	Rel Volume	0.70	Prev Close	28.42
Employees	131	LT Debt/Eq	0.03	Earnings	Aug 05 BMO	SMA200	32.18%	Avg Volume	1.24M	Price	29.18
IPO	May 23, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-12.56% -100.00%	Trades		Volume	864,192	Change	2.67%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Initiated	Guggenheim	Buy	$50
Sep-04-25	Initiated	Citizens JMP	Mkt Outperform	$41
Sep-04-25	Initiated	Barclays	Overweight	$40
Jul-22-25	Initiated	TD Cowen	Buy
Jul-10-25	Resumed	Goldman	Neutral	$25
Jun-26-25	Initiated	Wells Fargo	Overweight	$44
Nov-18-24	Initiated	Stephens	Overweight	$51
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27
Oct-24-24	Initiated	UBS	Buy	$50
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform	$50
Mar-08-24	Initiated	BTIG Research	Buy	$55
Aug-08-23	Initiated	SVB Securities	Outperform	$33
May-24-23	Initiated	Goldman	Buy	$32
Apr-24-23	Upgrade	Stifel	Hold → Buy	$18 → $24
Mar-23-23	Initiated	Berenberg	Buy	$26
Feb-28-23	Initiated	RBC Capital Mkts	Outperform	$25
Dec-28-22	Initiated	CapitalOne	Overweight	$29
Oct-27-22	Initiated	Citigroup	Buy	$26
Aug-15-22	Downgrade	Stifel	Buy → Hold	$16 → $13

Show Previous Ratings

Oct-20-25 06:30AM	IDEAYA Biosciences Announces Positive Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma in a Proffered Paper Oral Presentation at ESMO 2025 (PR Newswire)
06:00AM	IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress (PR Newswire)
Oct-17-25 09:55PM	Citizens JMP Remains Bullish on IDEAYA Biosciences (IDYA) (Insider Monkey) +5.67%
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
Oct-08-25 12:57AM	J.P. Morgan Remains Bullish on IDEAYA Biosciences (IDYA) (Insider Monkey)
06:00AM	Loading…
Sep-26-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-10-25 12:59AM	Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating (Insider Monkey)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire) -13.88%
08:00AM	IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy in MTAP-Deletion Urothelial Cancer (PR Newswire)
06:00AM	IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma (PR Newswire)
Sep-07-25 12:00PM	IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer (PR Newswire)
Sep-04-25 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy in MTAP-Deletion Non-Small Cell Lung Cancer (PR Newswire)
Sep-03-25 06:00AM	IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors (PR Newswire)
Sep-02-25 06:00AM	Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide (PR Newswire)
Aug-29-25 02:00PM	IDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress (PR Newswire)
06:00AM	Loading…
06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-25-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events (PR Newswire)
Aug-18-25 06:00AM	IDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025 (PR Newswire)
Aug-05-25 06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-01-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-24-25 11:47PM	TD Cowen Bullish on Ideaya's (IDYA) Oncology Pipeline (Insider Monkey) +5.08%
09:25AM	IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma (PR Newswire)
Jul-23-25 06:00AM	IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy (PR Newswire) +7.31%
Jul-22-25 01:01PM	IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC (PR Newswire)
Jul-21-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event (PR Newswire)
Jun-27-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-26-25 09:49AM	General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls (The Fly)
Jun-02-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events (PR Newswire) +6.69%
May-30-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-06-25 06:05AM	IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire) -13.29%
06:00AM	Loading…
06:00AM	IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors (PR Newswire)
May-05-25 07:51AM	Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
Apr-28-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events (PR Newswire)
Apr-27-25 09:22AM	Immunocore Holdings: A Name On My Watch List (Seeking Alpha)
Apr-25-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-16-25 08:52AM	Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later (Seeking Alpha)
Apr-14-25 06:00AM	IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma (PR Newswire)
Apr-10-25 06:00AM	IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy Combination in MTAP-Deletion Urothelial Cancer (PR Newswire)
Apr-02-25 11:49AM	Hospitals Experience FOMO In Adopting Delcath's PHP Treatment (Seeking Alpha) +10.70%
11:12AM	Why Ideaya Biosciences Is Down Despite Many Positives (Seeking Alpha)
Apr-01-25 06:00AM	IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events (PR Newswire) -9.83%
Mar-31-25 06:00AM	IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma (PR Newswire)
Mar-28-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-26-25 06:00AM	IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor (PR Newswire)
Mar-20-25 09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
Mar-05-25 02:45PM	IDEAYA Biosciences, Inc. (IDYA) Partners with ATTMOS for AI-Driven Drug Discovery Platform (Insider Monkey)
Mar-03-25 06:00AM	IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets (PR Newswire) -7.00%
Feb-28-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-14-25 09:35AM	Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA) (Zacks)
Feb-13-25 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss (Zacks) -5.42%
06:05AM	IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (PR Newswire)
06:00AM	IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC (PR Newswire)
Feb-10-25 12:00PM	All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy (Zacks)
06:00AM	IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer (PR Newswire)
Jan-31-25 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-30-25 05:07PM	Here's Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 (Insider Monkey)
Jan-27-25 06:00AM	IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events (PR Newswire)
Jan-12-25 12:00PM	IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance (PR Newswire)
Dec-29-24 06:00AM	IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors (PR Newswire)
Dec-27-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-17-24 06:00AM	IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma (PR Newswire)
Dec-16-24 06:00AM	IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers (PR Newswire)
Dec-11-24 06:00AM	IDEAYA Announces Agenda for Investor RandD Day Webcast on December 16, 2024 (PR Newswire)
06:00AM	IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 (PR Newswire)
Dec-10-24 06:00AM	IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer (PR Newswire)
Dec-09-24 06:00AM	IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor (PR Newswire)
Dec-06-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.38%
Dec-02-24 06:00AM	IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events (PR Newswire)
Nov-29-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-22-24 07:33AM	Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-18-24 06:00AM	IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer (PR Newswire)
Nov-12-24 06:00AM	IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day (PR Newswire)
Nov-11-24 06:00AM	IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen (PR Newswire)
06:00AM	Biocytogen Announces IDEAYAs Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise (Business Wire)
Nov-07-24 09:55AM	Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know (Zacks)
Nov-04-24 08:30AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
08:30AM	/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ (PR Newswire)
Nov-01-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-29-24 10:01AM	Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline (Zacks)
Oct-28-24 06:00AM	IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors (PR Newswire)
Oct-25-24 06:00AM	IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 (PR Newswire)
Oct-04-24 06:00AM	IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium (PR Newswire)
Sep-27-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-24-24 08:13AM	IDEAYAs rare cancer drug shows promise as company lays out Phase III plans (Clinical Trials Arena) -7.00%
Sep-23-24 06:00AM	IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma (PR Newswire)
Sep-22-24 09:00AM	IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 (PR Newswire)
Sep-18-24 06:00AM	IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel (PR Newswire)
Aug-30-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-26-24 06:00AM	IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-23-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-06-24 01:54PM	IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024 (InvestorPlace)
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Aug-01-24 10:01AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-31-24 06:00AM	IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen (PR Newswire)
06:00AM	Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program (Business Wire)
Jul-29-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event (PR Newswire)
Jul-23-24 09:55AM	How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97% (Zacks)
Jul-11-24 04:05PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) +6.16%
Jul-09-24 10:26PM	IDEAYA Announces Pricing of Public Offering (PR Newswire)
04:08PM	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hata Yujiro S	President and CEO	Feb 18 '25	Option Exercise	19.52	12,808	250,012	690,695	Feb 19 06:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IDYA

Ideaya Biosciences Inc

Upgrade your FINVIZ experience